Figure 1. Patients with well-controlled acromegaly treated with somatostatin analogues, pegvisomant or in combination after examination of polygraphy. Division in a group apnea-hypnea index (AHI) < 5 and AHI ≥ 5: mean ± SEM.
| Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc |
| Journal website http://www.jofem.org |
Original Article
Volume 7, Number 5, October 2017, pages 141-145
Obstructive Sleep Apnea Syndrome Is Less Frequent in Patients With Well-Controlled Acromegaly Treated With Somatostatin Analogues, Pegvisomant or in Combination
Figures
Tables
| Number/mean | Range | |
|---|---|---|
| Number | 29 | |
| Female | 12 | |
| Male | 17 | |
| Age (years) | 49 ± 14 | 25 - 73 |
| BMI (kg/m2) | 29.9 ± 5.4 | 20.8 - 29.9 |
| Disease duration (years) | 13 ± 8 | 2 - 32 |
| IGF-I (µg/L) | 184 ± 73 | 74 - 383 |
| Well-controlled acromegaly | 29 (100%) | |
| Surgery | 22 (76%) | |
| Radiation + surgery | 7 (24%) |
| Treatments/medications | AHI < 5 | AHI ≥ 5 | P |
|---|---|---|---|
| Age (years) | 47 ± 13 | 61 ± 9 | 0.037 |
| M/F | 9/16 | 2/2 | n.s. |
| BMI (kg/m2) | 30.0 ± 5.7 | 30.0 ± 3.0 | n.s. |
| Disease duration (years) | 12 ± 8 | 16 ± 1 | 0.01 |
| AHI | 2 ± 2 | 9 ± 4 | 0.05 |
| Epworth sleepiness scale score | 6 ± 4 | 4 ± 2 | n.s. |
| IGF-I (µg/L) | 187 ± 78 | 169 ± 30 | n.s. |
| AHI < 5 | AHI ≥ 5 | |
|---|---|---|
| Number | 25 (87%) | 4 (13%) |
| Previous treatment | ||
| Surgery | 19 (76%) | 3 (75%) |
| Radiation + surgery | 6 (24%) | 1 (25%) |
| Current medication | ||
| SSA | 9 (36%) | 2 (50%) |
| Pegvisomant | 10 (40%) | 1 (25%) |
| SSA + pegvisomant | 6 (24%) | 1 (25%) |